| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.HUMPATH.2008.11.014 |
| P698 | PubMed publication ID | 19269014 |
| P50 | author | Carsten Bokemeyer | Q1045499 |
| Ronald Simon | Q40046025 | ||
| P2093 | author name string | Guido Sauter | |
| Tim H Brümmendorf | |||
| Jakob R Izbicki | |||
| Andreas H Marx | |||
| Jussuf T Kaifi | |||
| Lars Tharun | |||
| Martina Mirlacher | |||
| Ana-Maria Dancau | |||
| Emre Yekebas | |||
| Johanna Muth | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 769-777 | |
| P577 | publication date | 2009-03-09 | |
| P1433 | published in | Human Pathology | Q15756731 |
| P1476 | title | HER-2 amplification is highly homogenous in gastric cancer. | |
| P478 | volume | 40 |
| Q38841254 | A low percentage of HER-2 amplification whereas indicates poor prognosis in salivary carcinoma ex pleomorphic adenoma: a study of 140 cases |
| Q88055520 | A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity |
| Q38691748 | An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis |
| Q36101895 | Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). |
| Q39686196 | Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells |
| Q44885327 | Are biopsy specimens predictive of HER2 status in gastric cancer patients? |
| Q54594739 | Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. |
| Q36950483 | Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial |
| Q37012387 | Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China |
| Q37373790 | Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases. |
| Q53424338 | Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers. |
| Q37700533 | Clinical significance of vimentin expression and Her-2 status in patients with gastric carcinoma |
| Q34631121 | Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review |
| Q53134672 | Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. |
| Q36999892 | Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). |
| Q98159085 | Comparing human epidermal growth factor receptor 2 amplification and expression using immunohistochemistry and silver in situ hybridisation in gastric carcinoma and lymph node metastasis |
| Q47096927 | Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer |
| Q33799233 | Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer |
| Q35006904 | Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma |
| Q51537752 | Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. |
| Q43635123 | Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice |
| Q34353223 | Correlation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection |
| Q36770491 | Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer |
| Q35594687 | Correlations of Human Epithelial Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological Characteristics in Gastric Cancer Patients with Curative Resection |
| Q24604411 | Critical appraisal of trastuzumab in treatment of advanced stomach cancer |
| Q34962039 | Current status of novel agents in advanced gastroesophageal adenocarcinoma |
| Q83525590 | Delineation of commonly deleted chromosomal regions in meningiomas by high-density single nucleotide polymorphism genotyping arrays |
| Q48379063 | Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. |
| Q37607824 | Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes |
| Q39363485 | Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis |
| Q34834419 | Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis |
| Q55066506 | Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites. |
| Q36666667 | Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. |
| Q46839142 | Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer |
| Q35562690 | Epigenetic clustering of gastric carcinomas based on DNA methylation profiles at the precancerous stage: its correlation with tumor aggressiveness and patient outcome |
| Q37960206 | Evolving standards of care in advanced gastric cancer |
| Q41812451 | Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer |
| Q26741859 | Gastric biomarkers: a global review |
| Q34642023 | Gastric cancer: Classification, histology and application of molecular pathology |
| Q35548468 | HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas |
| Q54508080 | HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. |
| Q36739953 | HER2 Expression in Gastric Adenocarcinoma-a Study in a Tertiary Care Centre in South India |
| Q51671698 | HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease. |
| Q26780318 | HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach |
| Q39080349 | HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q34223664 | HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature |
| Q42431264 | HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing |
| Q35538755 | HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis |
| Q83629811 | HER2 expression and its clinicopathological features in resectable gastric cancer |
| Q36849324 | HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population |
| Q54587084 | HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. |
| Q87469034 | HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides |
| Q26741253 | HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice |
| Q34324291 | HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. |
| Q35211263 | HER2 in solid tumors: more than 10 years under the microscope; where are we now? |
| Q35047997 | HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. |
| Q41880900 | HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH) |
| Q54489534 | HER2 status of gastric carcinoma and corresponding lymph node metastasis. |
| Q54312070 | HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible? |
| Q37824265 | Her-2/neu testing and therapy in gastroesophageal adenocarcinoma |
| Q84814743 | Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung |
| Q44867167 | Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas |
| Q35554809 | Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer |
| Q35700713 | Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma |
| Q51762437 | High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. |
| Q41350586 | Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics |
| Q55224220 | Human Epidermal Growth Factor Receptor 2 Status in Gastric Carcinomas with Distinctive Prevalent Cribriform Component. |
| Q51006230 | Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer. |
| Q35670454 | Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. |
| Q59798481 | Human epithelial growth factor receptor 2 in human salivary carcinoma ex pleomorphic adenoma: a potential therapeutic target |
| Q35195417 | Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. |
| Q35140953 | In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. |
| Q39535768 | Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent? |
| Q58553403 | Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) |
| Q54605374 | Low frequency of HER2 amplification and overexpression in early onset gastric cancer. |
| Q35768487 | Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer |
| Q37959106 | Molecular pathology of gastric carcinoma |
| Q33347546 | Nature meets nurture: molecular genetics of gastric cancer. |
| Q51232753 | Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. |
| Q53458025 | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. |
| Q37109776 | Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. |
| Q33895573 | Primary and acquired resistance to biologic therapies in gastrointestinal cancers |
| Q53128686 | Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. |
| Q36630742 | Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial |
| Q44736229 | Prognostic significance of HER2/neu expression in gastric cancer |
| Q41169570 | RNAi knockdown of C-erbB2 expression inhibits salivary gland adenoid cystic carcinoma SACC-83 cell growth in vitro |
| Q38001383 | Randomized trials and quality assurance in gastric cancer surgery |
| Q34730478 | Serum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinoma |
| Q37941807 | Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma |
| Q38097675 | Targeting the human epidermal growth factor receptor 2 in esophageal cancer |
| Q34648886 | The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer |
| Q38210070 | The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey |
| Q37894669 | The role of tissue microarray in the era of target-based agents. |
| Q36595556 | The search for protein overexpression and HER2 gene amplification in gastric cancer by immunohistochemistry and in situ hybridization: experience of the CHU Hassan II of Fez |
| Q33764191 | The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing |
| Q54360289 | Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. |
| Q37633540 | Trastuzumab for gastric cancer |
| Q28077666 | Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives |
| Q54676467 | [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. |
Search more.